NCT06867471Completed
Effects of Exogenous Ketosis on Proteinuria and Renal Function
Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients With Chronic Kidney Disease and Patients With Polycystic Kidney Disease
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 20 Nov 2024
- Start date
- 11 Sept 2024
- Primary completion date
- 10 Dec 2025
- Lead sponsor
- Gødstrup Hospital
- NCT number
- NCT06867471
What you commit to
- Study type: Interventional
- Participants enrolled: 45
- From 11 Sept 2024 to the primary completion date, 10 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Kidney transplant
- Alcohol or drug abuse
- Treatment with nitrate
Other illness
- Diabetes Mellitus type 1
- Heart Failure
- Liver Disease
- Malignant diseases (except skin cancer)
- Recent acute myocardial infarction (AMI), apoplexia/transient ischemic attack (TIA) (within 3 months of inclusion)
Other
- Pregnancy or breast feeding
- Periodic fasting within four weeks of inclusion
- Routinely intake of ketogenic diet within four weeks of inclusion
Who the study is looking for
- Study A (patients with CKD):
- ACR \> 200 mg/g \<3000 mg/g
- eGFR \>30 ml/min/1,73m2
- Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion
- Safe contraception if women in childbearing age
- Study B (patients with PKD):
- Prior diagnose with PKD
- eGFR \>30 ml/min/1,73m2
- Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion
- Safe contraception if women in childbearing age
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Clinic in Nephrology and Hypertension, Gødstrup Region Hospital Coordinator of this site? Confirm its status | Herning | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.